AstraZeneca and Daiichi Sankyo have revealed that their new drug has shown a ‘meaningful improvement’ in survivability rates in patients suffering from an aggressive form of breast cancer.
The FTSE 100 pharma giant said a late-stage trial of its Enhertu treatment showed the drug demonstrated a ‘highly statistically significant’ improvement on an existing drug cocktail when it was combined with another medicine, Pertuzumab.
The trial was testing Enhertu’s effectiveness against HER2-positive metastatic breast cancer.
Only 30 per cent of those diagnosed with the illness survive beyond five years.
AstraZeneca said the results from the trial were the first in more than a decade to show a new medicine had been more effective across a broad range of patients at treating the illness, against the current standard of care.
Breakthrough: Astrazeneca said a trial of its Enhertu treatment showed the drug demonstrated a ‘highly statistically significant’ improvement on an existing treatment.
DIY INVESTING PLATFORMS
AJ Bell
AJ Bell
Easy investing and ready-made portfolios
Hargreaves Lansdown
Hargreaves Lansdown
Free fund dealing and investment ideas
interactive investor
interactive investor
Flat-fee investing from £4.99 per month
Saxo
Saxo
Get £200 back in trading fees
Trading 212
Trading 212
Free dealing and no account fee
Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.
